Zentalis Pharmaceuticals Llc Stock Today
| ZNTL Stock | USD 1.98 0.07 3.66% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Zentalis Pharmaceuticals is selling for 1.98 as of the 24th of March 2025. This is a 3.66 percent increase since the beginning of the trading day. The stock's lowest day price was 1.87. Zentalis Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 24th of December 2024 and ending today, the 24th of March 2025. Click here to learn more.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. The company was incorporated in 2014 and is based in New York, New York. The company has 71.27 M outstanding shares of which 5.19 M shares are at this time shorted by private and institutional investors with about 2.27 trading days to cover. More on Zentalis Pharmaceuticals Llc
Moving against Zentalis Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Zentalis Stock Highlights
| President CEO | Julie MBA |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Zentalis Pharmaceuticals Llc (ZNTL) is traded on NASDAQ Exchange in USA. It is located in 1359 Broadway, New York, NY, United States, 10018 and employs 124 people. Zentalis Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 136.12 M. Zentalis Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 71.27 M outstanding shares of which 5.19 M shares are at this time shorted by private and institutional investors with about 2.27 trading days to cover.
Zentalis Pharmaceuticals Llc currently holds about 455.22 M in cash with (207.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Zentalis Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationZentalis Pharmaceuticals Llc retains a total of 71.27 Million outstanding shares. The majority of Zentalis Pharmaceuticals outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Zentalis Pharmaceuticals to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in Zentalis Pharmaceuticals Llc. Please pay attention to any change in the institutional holdings of Zentalis Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that almost six million four hundred seventy-eight thousand twenty-five invesors are currently shorting Zentalis Pharmaceuticals expressing very little confidence in its future performance.
Check Zentalis Ownership Details
Zentalis Pharmaceuticals Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Zentalis Pharmaceuticals market risk premium is the additional return an investor will receive from holding Zentalis Pharmaceuticals long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.56) | |||
| Total Risk Alpha | (0.26) | |||
| Treynor Ratio | 2.72 |
Zentalis Stock Against Markets
Zentalis Pharmaceuticals Corporate Management
| Vincent Vultaggio | VP Officer | Profile | |
| Kevin Bunker | CoFounder Officer | Profile | |
| Carrie MD | Chief Officer | Profile | |
| Adrian MD | Executive Development | Profile | |
| Mark Lackner | Chief Strategy | Profile | |
| Ingmar MD | Chief Officer | Profile | |
| Kimberly Freeman | Chief Officer | Profile |
Already Invested in Zentalis Pharmaceuticals Llc?
The danger of trading Zentalis Pharmaceuticals Llc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zentalis Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zentalis Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zentalis Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Zentalis Pharmaceuticals is a strong investment it is important to analyze Zentalis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis Pharmaceuticals' future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.